Nestle divests peanut allergy treatment business Palforzia to Stallergenes Greer
Switzerland: Nestle has announced that it has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. The transaction was closed upon signing.
This agreement follows Nestlé's announcement last year that it would conduct a strategic review of Palforzia. Nestle will receive milestone payments and ongoing royalties from Stallergenes Greer.
Read also: Cipla Medpro South Africa to acquire Actor Pharma for Rs 403 crore
"We are confident that Stallergenes Greer will take Palforzia forward and ensure this unique treatment supports patients around the world," said Greg Behar, CEO of Nestlé Health Science. "At the same time, the divestiture allows Nestlé Health Science to focus on its core strengths and key growth drivers."
There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
Read also: Nestle signs an agreement for Alzheimer's disease diagnostic test
